
FDA Proposes Permanently Excluding GLP-1 Ingredients From Large Scale Compounding Facilities
The U.S. Food and Drug Administration proposed on April 30, 2026, to permanently exclude semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that large-scale compounding facilities are legally permitted to use, finding no clinical need for outsourcing facilities to compound these drugs now that brand-name versions are















